Disgraced researcher blames GSK pressure for Chinese data lapses

GlaxoSmithKline ($GSK) wasn't the only Big Pharma company to set up R&D operations in China. But a feature in Bloomberg today highlights GSK's unusual decision to give its research division there the lead role in neuroscience drug development. Now, a researcher who left the company under a cloud blames a high-pressure corporate culture that insists on quick results for much of what went wrong. Report